259 related articles for article (PubMed ID: 26334458)
1. Frequency, predictors, and consequences of maintenance infliximab therapy intensification in ulcerative colitis.
Fernández-Salazar L; Barrio J; Muñoz F; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; González-Redondo G; Fernández N; Santos F; Sánchez-Ocaña R; Joao D;
Rev Esp Enferm Dig; 2015 Sep; 107(9):527-33. PubMed ID: 26334458
[TBL] [Abstract][Full Text] [Related]
2. Infliximab in ulcerative colitis: real-life analysis of factors predicting treatment discontinuation due to lack of response or colectomy: ECIA (ACAD Colitis and Infliximab Study).
Fernández-Salazar L; Muñoz F; Barrio J; Muñoz C; Pajares R; Rivero M; Prieto V; Legido J; Bouhmidi A; Herranz M; Fernández N; Sánchez-Ocaña R; Joao D; Santos F
Scand J Gastroenterol; 2016; 51(2):186-95. PubMed ID: 26200929
[TBL] [Abstract][Full Text] [Related]
3. Long-term combination therapy with infliximab plus azathioprine predicts sustained steroid-free clinical benefit in steroid-dependent ulcerative colitis.
Armuzzi A; Pugliese D; Danese S; Rizzo G; Felice C; Marzo M; Andrisani G; Fiorino G; Nardone OM; De Vitis I; Papa A; Rapaccini GL; Guidi L
Inflamm Bowel Dis; 2014 Aug; 20(8):1368-74. PubMed ID: 24983979
[TBL] [Abstract][Full Text] [Related]
4. Extent of Early Clinical Response to Infliximab Predicts Long-term Treatment Success in Active Ulcerative Colitis.
Murthy SK; Greenberg GR; Croitoru K; Nguyen GC; Silverberg MS; Steinhart AH
Inflamm Bowel Dis; 2015 Sep; 21(9):2090-6. PubMed ID: 26099066
[TBL] [Abstract][Full Text] [Related]
5. Long-term outcomes of infliximab treatment and predictors of response in 195 patients with ulcerative colitis: a hospital-based cohort study from Korea.
Seo H; Chang K; Lee SH; Song EM; Kim GU; Seo M; Lee HS; Hwang SW; Yang DH; Kim KJ; Ye BD; Byeon JS; Myung SJ; Yang SK; Park SH
Scand J Gastroenterol; 2017 Aug; 52(8):857-863. PubMed ID: 28502189
[TBL] [Abstract][Full Text] [Related]
6. Infliximab Dose Escalation as an Effective Strategy for Managing Secondary Loss of Response in Ulcerative Colitis.
Taxonera C; Barreiro-de Acosta M; Calvo M; Saro C; Bastida G; Martín-Arranz MD; Gisbert JP; García-Sánchez V; Marín-Jiménez I; Bermejo F; Chaparro M; Ponferrada Á; Martínez-Montiel MP; Pajares R; de Gracia C; Olivares D; Alba C; Mendoza JL; Fernández-Blanco I
Dig Dis Sci; 2015 Oct; 60(10):3075-84. PubMed ID: 26044830
[TBL] [Abstract][Full Text] [Related]
7. [Clinical outcome after discontinuation of infliximab in patients with ulcerative colitis in deep remission].
Muñoz Villafranca C; Bravo Rodríguez MT; Ortiz de Zárate J; Arreba González P; García Kamiruaga I; Heras Martín JI; Cabezudo Gil P; Orive Cura V
Gastroenterol Hepatol; 2016; 39(7):442-8. PubMed ID: 26948837
[TBL] [Abstract][Full Text] [Related]
8. Short- and Long-Term Outcomes of Infliximab Treatment for Steroid-Refractory Ulcerative Colitis and Related Prognostic Factors: A Single-Center Retrospective Study.
Nasuno M; Miyakawa M; Tanaka H; Motoya S
Digestion; 2017; 95(1):67-71. PubMed ID: 28052276
[TBL] [Abstract][Full Text] [Related]
9. Similar Short- and Long-term Colectomy Rates with Ciclosporin and Infliximab Treatment in Hospitalised Ulcerative Colitis Patients.
Duijvis NW; Ten Hove AS; Ponsioen CI; van den Brink GR; Buskens CJ; Bemelman WA; Te Velde AA; D'Haens GR; Löwenberg M
J Crohns Colitis; 2016 Jul; 10(7):821-7. PubMed ID: 26818660
[TBL] [Abstract][Full Text] [Related]
10. Long-Term Outcome of Patients with Ulcerative Colitis and Primary Non-response to Infliximab.
Papamichael K; Rivals-Lerebours O; Billiet T; Vande Casteele N; Gils A; Ferrante M; Van Assche G; Rutgeerts PJ; Mantzaris GJ; Peyrin-Biroulet L; Vermeire S
J Crohns Colitis; 2016 Sep; 10(9):1015-23. PubMed ID: 27022161
[TBL] [Abstract][Full Text] [Related]
11. Intensified Infliximab Induction is Associated with Improved Response and Decreased Colectomy in Steroid-Refractory Paediatric Ulcerative Colitis.
Church PC; Ho S; Sharma A; Tomalty D; Frost K; Muise A; Walters TD; Griffiths AM
J Crohns Colitis; 2019 Aug; 13(8):982-989. PubMed ID: 30715240
[TBL] [Abstract][Full Text] [Related]
12. C-reactive protein level at 2 weeks following initiation of infliximab induction therapy predicts outcomes in patients with ulcerative colitis: a 3 year follow-up study.
Iwasa R; Yamada A; Sono K; Furukawa R; Takeuchi K; Suzuki Y
BMC Gastroenterol; 2015 Aug; 15():103. PubMed ID: 26271624
[TBL] [Abstract][Full Text] [Related]
13. Infliximab or cyclosporine as rescue therapy in hospitalized patients with steroid-refractory ulcerative colitis: a retrospective observational study.
Sjöberg M; Walch A; Meshkat M; Gustavsson A; Järnerot G; Vogelsang H; Hertervig E; Novacek G; Friis-Liby I; Blomquist L; Angelberger S; Karlen P; Grännö C; Vilien M; Ström M; Verbaan H; Hellström PM; Dejaco C; Magnuson A; Halfvarson J; Reinisch W; Tysk C
Inflamm Bowel Dis; 2012 Feb; 18(2):212-8. PubMed ID: 21438096
[TBL] [Abstract][Full Text] [Related]
14. Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience.
Yamada S; Yoshino T; Matsuura M; Minami N; Toyonaga T; Honzawa Y; Tsuji Y; Nakase H
BMC Gastroenterol; 2014 Apr; 14():80. PubMed ID: 24758588
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of sustained combination therapy for at least 6 months with thiopurines and infliximab in patients with ulcerative colitis in clinical remission: a retrospective multicenter French experience.
Filippi J; Laharie D; Michiels C; Flamand M; Bouguen G; Nancey S; Presles E; Paul S; Schneider S; Hébuterne X; Roblin X
J Crohns Colitis; 2015 Mar; 9(3):252-8. PubMed ID: 25588386
[TBL] [Abstract][Full Text] [Related]
16. Duration of disease may predict response to infliximab in pediatric ulcerative colitis.
Mir SA; Nagy-Szakal D; Smith EO; Gilger MA; Kellermayer R
J Clin Gastroenterol; 2014 Mar; 48(3):248-52. PubMed ID: 24129407
[TBL] [Abstract][Full Text] [Related]
17. Examining maintenance care following infliximab salvage therapy for acute severe ulcerative colitis.
Seah D; Choy MC; Gorelik A; Connell WR; Sparrow MP; Van Langenberg D; Hebbard G; Moore G; De Cruz P
J Gastroenterol Hepatol; 2018 Jan; 33(1):226-231. PubMed ID: 28618062
[TBL] [Abstract][Full Text] [Related]
18. First trough level of infliximab at week 2 predicts future outcomes of induction therapy in ulcerative colitis-results from a multicenter prospective randomized controlled trial and its post hoc analysis.
Kobayashi T; Suzuki Y; Motoya S; Hirai F; Ogata H; Ito H; Sato N; Ozaki K; Watanabe M; Hibi T
J Gastroenterol; 2016 Mar; 51(3):241-51. PubMed ID: 26162647
[TBL] [Abstract][Full Text] [Related]
19. Post-induction infliximab trough levels and disease activity in the clinical evolution of pediatric ulcerative colitis.
Moore H; Dolce P; Devas N; Baldassano R; Martinelli M
United European Gastroenterol J; 2020 May; 8(4):425-435. PubMed ID: 32213038
[TBL] [Abstract][Full Text] [Related]
20. High-Dose Infliximab Rescue Therapy for Hospitalized Acute Severe Ulcerative Colitis Does Not Improve Colectomy-Free Survival.
Chao CY; Al Khoury A; Aruljothy A; Restellini S; Wyse J; Afif W; Bitton A; Lakatos PL; Bessissow T
Dig Dis Sci; 2019 Feb; 64(2):518-523. PubMed ID: 30446928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
